{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2002"],"condition":["Kidney Neoplasms","Breast Neoplasm","Lung Neoplasm","Ovarian Neoplasm","Ovarian Neoplasms","Renal Neoplasm","Pancreatic Neoplasms","Breast Neoplasms","Lung Neoplasms","Pancreatic Neoplasm","Neoplasms","Cancer"],"disease":["Kidney Neoplasms","Breast Neoplasm","Lung Neoplasm","Ovarian Neoplasm","Ovarian Neoplasms","Renal Neoplasm","Pancreatic Neoplasms","Breast Neoplasms","Lung Neoplasms","Pancreatic Neoplasm","Neoplasms","Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2007413"],"location":["United States"],"study_start_month":["6"],"keyword":["Prostate neoplasm","Gene, HER2","Colorectal neoplasm","Clinical Trial, Phase I"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2","description":"The purpose of this study is to investigate a safe dose of TAK-165, once daily (QD), in patients with HER2-tumor expression.","dates":{"creation":"2002-06-15"},"accession":"2007413","cross_references":{"ClinicalTrials___gov":["NCT00034281"],"International Clinical Trials Registry Platform":["U1111-1127-6123"]}}